Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Hugo Arasanz

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

H. Arasanz1, M. Zuazo2, M. Martínez Aguillo1, B. Hernández Marín1, G. Fernández-Hinojal1, A.I. Bocanegra2, I. Morilla Ruiz1, M. Gato-Cañas3, L. Teijeira1, P. Sala1, M.J. García-Granda2, R. Vera1, G. Kochan2, D. Escors2

Author affiliations

  • 1 Medical Oncology, Complejo Hospitalario de Navarra, 31008 - Pamplona/ES
  • 2 Immunomodulation-oncology, Navarrabiomed, 31008 - Pamplona/ES
  • 3 Av. De Pío Xii, 55, Centro de Investigación Médica Aplicada, Pamplona/ES
More

Resources

Abstract 2120

Background

Hyperprogressive disease (HPD) is a new pattern of tumor response described with immune checkpoint inhibitors (ICI), characterized by a sharp acceleration of tumor growth after the administration of the treatment. Several definitions based on clinical and/or radiological criteria have been proposed, although different factors limit their applicability. The mechanistic rationale has still not been elucidated. Our group has monitored lymphocyte populations in peripheral blood from non-small cell lung cancer patients (NSCLC) under ICI treatment with flow cytometry, and correlated the findings with HPD.

Methods

41 NSCLC patients treated with ICI after progression to ≥ 1 lines of chemotherapy for advanced disease have been included. We analyzed lymphocyte subpopulations from peripheral blood samples obtained immediately before the administration of the 1st and 2nd cycle of ICI. The expression of the following markers has been considered: CD3, CD4, CD8, CD27, CD28, CD45RA, CD62L, PD1. We correlated the findings with HPD as defined by TGR (Champiat S, 2017) and TGKR (Sâada-Bouzid E, 2017).

Results

Overall response rate (ORR) was 23.8%, and disease control rate (DCR) was 31%. 10 patients (23.8%) presented HPD by TGKR, and 7 patients (16.7%) by TGR. 9 patients (21.4%) could not be evaluated for HPD, mainly due to progression by non-measurable disease or death before further radiological. Median progression free survival (mPFS) was 6 weeks for HPD by TGR and 6.3 weeks by TGKR. We found that the mean proportion of post/pre-treatment LT CD4+ CD27- CD28- was significantly higher for HPD patients (1.86; CI95% 1.14 to 2.58 than non-HPD (1.09; CI95% 0.89 to 1.30) (p = 0.0033). An increase > 30% in LT CD4+/CD27-/CD28- after the first cycle of immunotherapy was associated with fast progression (ORR 0%, mPFS 6 weeks [CI95% 5.8 to 6.2], 8-weeks PFS 0%). Cohen’s kappa between HPD by TGR and by LT was 0.503 (p = 0.004).

Conclusions

HPD as defined by LT CD4+ CD27- CD28- burst > 30% might complement the limitations of radiological criteria as it does not require the evaluation of the tumor kynetics previous to the beggining of immunotherapy, nor it is influenced by non-measurable disease or tumor burden.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

AECC, ISCIII.

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings